

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

**VOLUNTARY ANNOUNCEMENT
REGISTRATION APPLICATION OF
TaurusNXT® NON-GLUTARALDEHYDE CROSSLINKED
DRY-TISSUE TRANSCATHETER AORTIC VALVE
REPLACEMENT SYSTEM ACCEPTED BY THE NMPA**

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that recently, the Company received a confirmation letter from the National Medical Products Administration of the People’s Republic of China (the “**NMPA**”), confirming its acceptance of the registration application of TaurusNXT® *Non-glutaraldehyde Crosslinked Dry-tissue Transcatheter Aortic Valve Replacement* (“**TAVR**”) system (the “**System**”).

TaurusNXT® is a third-generation TAVR system internally developed by the Company. It incorporates patented non-glutaraldehyde bio-tissue crosslinking technology that removes the main source of valve calcification which is the primary cause of prosthetic valve degeneration. This technology is designed to enhance the durability and biocompatibility of the prosthetic aortic valve (“**PAV**”). Moreover, compared to traditional dry tissue technologies that use glycerin, the System adopts an ultra-low temperature vacuum freeze-drying technology. This approach helps maintain the physical integrity of the valve tissue while enabling the PAV to be pre-loaded into the delivery catheter system (“**DCS**”). The DCS of TaurusNXT® has also been upgraded with both retrievability and steerability features, which assist physicians in guiding the PAV to the target implant position more easily, thereby further improving procedural safety.

The System has been accepted by the Special Review and Approval Procedure for Innovative Medical Devices of the NMPA and will be prioritised in the subsequent appraisal and approval procedures.

**THE COMPANY MAY NOT BE ABLE TO ULTIMATELY MARKET TaurusNXT®
NON-GLUTARALDEHYDE CROSSLINKED DRY-TISSUE TAVR SYSTEM
SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL
INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN
THE SHARES OF THE COMPANY.**

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, December 7, 2025

As of the date of this announcement, the Board comprises Dr. Yi ZHANG, Mrs. Ping Ye ZHANG and Ms. Hong YE as executive Directors, Mr. Jifeng GUAN, Mr. Fei CHEN, Mr. Jun YANG as non-executive Directors, and Dr. Stephen Newman OESTERLE, Mr. Robert Ralph PARKS, Mr. Wai Ming YIP, Mr. Huacheng WEI as independent non-executive Directors.